Esperion Therapeutics ESPR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Product | ||||||
| Collaboration revenue | $250.28M+2.7% | $243.67M+55.7% | $156.47M+20.1% | $130.3M+15.1% | $113.19M-42.3% | |
| Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received | $152.1M+2.2% | $148.8M+5.2% | $141.5M+20.9% | $117M-3.6% | $121.4M-40.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Esperion Therapeutics break its business down?
- Esperion Therapeutics (ESPR) reports total revenues by product across 2 parts — Collaboration revenue and Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received. Each is extracted from the segment footnotes and tracked over time.
- Where does Esperion Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Esperion Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
